Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy

Chen, Huaiwen; Gao, Jie; Lü, Ying; Kou, Geng; Zhang, He; Fan, Li; Sun, Zhiguo; Guo, Yajun; Zhong, Yanqiang

doi:10.1016/j.jconrel.2008.03.010

Cited by 88 publications

(50 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The development of CD133-SAL-NP was completed by the conjugation of the CD133 antibody to SAL-NPs (16). A solution of SAL-NPs (2.5 mg/ml) was activated with 50 mM NHS and 100 mM EDC for 60 min at 25˚C, and the activated SAL-NPs was washed with PBS twice, incubated with CD133 antibodies (1 ml; 0.05 mg/ml; 1:10) for 6 h at 25˚C to produce CD133-SAL-NP, which were washed and stored at 4˚C until use.…”

Section: Development Of Salinomycin-loaded Plga Nanoparticlesmentioning

confidence: 99%

“…Several salinomycin-loaded nanoparticles have been developed for its delivery to CSCs, and these have achieved an improved therapeutic effect over free salinomycin (13,14). Poly(lactic-co-glycolic acid) (PLGA) nanoparticles are widely used due to their safety record in humans (15,16). PLGA nanoparticles are frequently modified with poly(ethylene glycol) (PEG) to increase their in vivo circulation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles

Huang

Deng

2018

Oncol Lett

View full text Add to dashboard Cite

Abstract. Ovarian cancer is the most lethal gynecologic malignancy, and ovarian cancer stem cells (CSCs) serve a pivotal function in the metastasis and recurrence of ovarian cancer. Multiple previous studies have validated CD133 as a marker of ovarian CSCs. Although salinomycin is a promising therapeutic agent that has been demonstrated to kill CSCs in various types of cancer, poor aqueous solubility hampers its clinical application. The present study used salinomycin-loaded poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles conjugated with CD133 antibodies (CD133-SAL-NP) to eliminate CD133 + ovarian CSCs. The results revealed that CD133-SAL-NPs were of an appropriate size (149.2 nm) and exhibited sustained drug release. CD133-SAL-NPs efficiently bound to CD133 + ovarian cancer cells, resulting in an increased cytotoxic effect in CD133 + ovarian cancer cells, compared with the untargeted SAL-NPs and salinomycin. CD133-SAL-NPs reduced the percentage of CD133 + ovarian CSCs in ovarian cells more effectively than treatment with salinomycin or SAL-NPs, suggesting that CD133-SAL-NP targeted CD133 + ovarian CSCs. In nude mice bearing ovarian cancer xenografts, CD133-SAL-NPs exerted improved therapeutic effects compared with SAL-NPs and salinomycin. Thus, CD133 was demonstrated to be a promising target for drug delivery to ovarian CSCs, and may be useful as an agent to inhibit the growth of ovarian cancer by targeting CD133 + ovarian CSCs. CD133-SAL-NPs may therefore represent a promising approach for the treatment of ovarian cancer.

show abstract

Section: Development Of Salinomycin-loaded Plga Nanoparticlesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles

Huang

Deng

2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…The result was compared with a standard curve obtained by OV in the concentration range of 15.6-1,000 µg/mL. 30,32 cell viability assay DCs were seeded at a density of 10,000 cells per well in 96-well plates with complete media containing alpha MEM, 20% FBS, 5 ng/mL GM-CSF, and 1% penicillin-streptomycinamphotericin B cocktail. 33 For the assay, MTS reagent was used following the manufacturer's directions.…”

Section: Methodsmentioning

confidence: 99%

Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine

Jahan¹,

Sadat²,

Haddadi³

2018

IJN

View full text Add to dashboard Cite

The aim of this research was to develop a targeted antigen–adjuvant assembled delivery system that will enable dendritic cells (DCs) to efficiently mature to recognize antigens released from tumor cells. It is important to target the DCs with greater efficiency to prime T cell immune responses. In brief, model antigen, ovalbumin (OV), and monophosphoryl lipid A adjuvant were encapsulated within the nanoparticle (NP) by double emulsification solvent evaporation method. Targeted NPs were obtained through ligand incorporation via physical adsorption or chemical conjugation process. Intracellular uptake of the NPs and the maturation of DCs were evaluated with flow cytometry. Remarkably, the developed delivery system had suitable physicochemical properties, such as particle size, surface charge, OV encapsulation efficiency, biphasic OV release pattern, and safety profile. The ligand modified formulations had higher targeting efficiency than the non-tailored NPs. This was also evident when the targeted formulations expressed comparatively higher fold increase in surface activation markers such as CD40, CD86, and major histocompatibility complex class II molecules. The maturation of DCs was further confirmed through secretion of extracellular cytokines compared to control cells in the DC microenvironment. Physicochemical characterization of NPs was performed based on the polymer end groups, their viscosities, and ligand-NP bonding type. In conclusion, the DC stimulatory response was integrated to develop a relationship between the NP structure and desired immune response. Therefore, the present study narrates a comparative evaluation of some selected parameters to choose a suitable formulation useful for in vivo cancer immunotherapy.

show abstract

“…Fornaguera et al [29], in contrast, took advantage of the fluorescent properties of galantamine drug to quantify its encapsulation efficiency in polymeric nanoparticles and its release. Chen et al [30] used fluorimetry to confirm covalent bond formation onto polymeric nanoparticle surface. In addition, since the excitation/emission are wavelength Although the varied uses of fluorescence, it has two main drawbacks ( Table 2): only some materials have fluorescence and the fluorescence lifetime is limited, with a wavelength dependent on the specific compound [28].…”

Section: Spectroscopic Techniquesmentioning

confidence: 99%

Analytical Methods to Characterize and Purify Polymeric Nanoparticles

Fornaguera

Solans

2018

International Journal of Polymer Science

View full text Add to dashboard Cite

Advances in polymeric nanoparticles as novel nanomedicines have opened a new class of diagnostic and therapeutic tools for many diseases. However, although the benchtop research studies in the nanoworld are numerous, their translation to currently marketed products is still limited. This lack of transference can be attributed, among other factors, to problems with nanomedicine characterization. Characterization techniques at the nanoscale could be divided in three categories: characterization of physicochemical properties (e.g., size and surface charge), characterization of nanomaterials interactions with biological components (e.g., proteins from the blood), and analytical characterization and purification methods. Currently available literature of this last group only describes methodologies applied for a specific type of nanomaterial or even methods used for bulk materials, which are not completely applicable to nanomaterials. For this reason, the current review aims to become a scholastic guide for those scientists starting in the nanoworld, giving them a description of analytical characterization techniques aimed to analyze polymers forming nanoparticles and possible forms to purify them before being used in preclinical and clinical applications.

show abstract

Preparation and characterization of PE38KDEL-loaded anti-HER2 nanoparticles for targeted cancer therapy

Cited by 88 publications

References 32 publications

The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles

The enhanced delivery of salinomycin to CD133+ ovarian cancer stem cells through CD133 antibody conjugation with poly(lactic-co-glycolic acid)-poly(ethylene glycol) nanoparticles

Design and immunological evaluation of anti-CD205-tailored PLGA-based nanoparticulate cancer vaccine

Analytical Methods to Characterize and Purify Polymeric Nanoparticles

Contact Info

Product

Resources

About